公开(公告)号：EP3253408A1

公开(公告)日：2017-12-13

申请号：EP16747327.1

申请日：2016-02-05

Applicant: STC.UNM ,  Wilson, Bridget S. ,  Winter, Stuart, S. ,  Erasmus, Michael, Frank ,  Horowitz, Michael

Inventor： WILSON, Bridget, S. ,  WINTER, Stuart, S. ,  ERASMUS, Michael, Frank ,  HOROWITZ, Michael

IPC: A61K39/00 ,  A61P35/02

CPC classification number: C07K16/2803 ,  A61K39/3955 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/35 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92 ,  A61K2300/00

Abstract: This disclosure describes the identification of pre-B Cell Receptor (pre-BCR) antagonists and the use of pre-BCR antagonists as a targeted therapy. The compositions and methods generally involve a composition that includes a pre-B cell receptor (pre-BCR) antagonist and is engineered for expression as a T cell chimeric receptor. In some embodiments, the pre-BCR antagonists can include an anti-pre-BCR antibody.

公开(公告)号：AU2016215110A1

公开(公告)日：2017-09-21

申请号：AU2016215110

申请日：2016-02-05

Applicant: STC UNM ,  WILSON BRIDGET ,  WINTER STUART ,  ERASMUS MICHAEL ,  HOROWITZ MICHAEL

Inventor： WILSON BRIDGET S ,  WINTER STUART S ,  ERASMUS MICHAEL FRANK ,  HOROWITZ MICHAEL

IPC: A61K39/00 ,  A61P35/02

Abstract: This disclosure describes the identification of pre-B Cell Receptor (pre-BCR) antagonists and the use of pre-BCR antagonists as a targeted therapy. The compositions and methods generally involve a composition that includes a pre-B cell receptor (pre-BCR) antagonist and is engineered for expression as a T cell chimeric receptor. In some embodiments, the pre-BCR antagonists can include an anti-pre-BCR antibody.

公开(公告)号：USD728691S1

公开(公告)日：2015-05-05

申请号：US29456780

申请日：2013-06-04

Applicant: Erasmus Michael Carter

Designer： Erasmus Michael Carter

公开(公告)号：USD728692S1

公开(公告)日：2015-05-05

申请号：US29484830

申请日：2014-03-13

Applicant: Erasmus Michael Carter

Designer： Erasmus Michael Carter

公开(公告)号：WO2016127043A1

公开(公告)日：2016-08-11

申请号：PCT/US2016/016753

申请日：2016-02-05

Applicant: STC.UNM ,  WILSON, Bridget, S. ,  WINTER, Stuart, S. ,  ERASMUS, Michael, Frank ,  HOROWITZ, Michael

Inventor： WILSON, Bridget, S. ,  WINTER, Stuart, S. ,  ERASMUS, Michael, Frank ,  HOROWITZ, Michael

IPC: A61K39/00 ,  A61P35/02

CPC classification number: C07K16/2803 ,  A61K39/3955 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/35 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92 ,  A61K2300/00

Abstract: This disclosure describes the identification of pre-B Cell Receptor (pre-BCR) antagonists and the use of pre-BCR antagonists as a targeted therapy. The compositions and methods generally involve a composition that includes a pre-B cell receptor (pre-BCR) antagonist and is engineered for expression as a T cell chimeric receptor. In some embodiments, the pre-BCR antagonists can include an anti-pre-BCR antibody.

Abstract translation: 本公开描述了B细胞前受体（前BCR）拮抗剂的鉴定以及使用前BCR拮抗剂作为靶向治疗。 组合物和方法通常涉及包含前B细胞受体（前BCR）拮抗剂的组合物，并且被工程化以用作T细胞嵌合受体的表达。 在一些实施方案中，前BCR拮抗剂可以包括抗前BCR抗体。